No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BNTX240621C60000
- 36.00
- 0.000.00%
15min DelayNot Open Jun 18 15:59 ET
0.00High0.00Low
0.00Open36.00Pre Close0 Volume2 Open Interest60.00Strike Price0.00Turnover1063.34%IV11.28%PremiumJun 21, 2024Expiry Date26.27Intrinsic Value100Multiplier1DDays to Expiry9.73Extrinsic Value100Contract SizeAmericanOptions Type0.8067Delta0.0044Gamma2.40Leverage Ratio-5.9706Theta0.0015Rho1.93Eff Leverage0.0159Vega
Intraday
- 5D
- Daily
No Data
News
FDA Puts Partial Clinical Hold on BioNTech's ADC Trial After Fatalities
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
CCORF analyst John Newman maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $171.According to TipRanks data, the analyst has a success rate of 39.0% and a total averag
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $146
BofA Securities analyst Tazeen Ahmad maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $146.According to TipRanks data, the analyst has a success rate of 48.3% and a t
US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial
BioNTech's (22UA.F) partner MediLink Therapeutics (Suzhou) notified the company that the US Food and Drug Administration placed a partial hold on new patient enrollment for a phase 1 trial assessing i
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Express News | BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202
Comments
$BioNTech(BNTX.US$ trashy stock
Morning Movers
Gapping up
$Disney(DIS.US$ 's stock enjoyed a 1.2% increase after a company spokesperson responded to activist investor Nelson Peltz's criticisms regarding the company's movie casting choices, using it as a reason to argue against his appointment to Disney's board.
$Masimo(MASI.US$ 's stock surged by 13% on news from the Wall Street Journal that Politan Capital Management is looking to propose two additional m...
Gapping up
$Disney(DIS.US$ 's stock enjoyed a 1.2% increase after a company spokesperson responded to activist investor Nelson Peltz's criticisms regarding the company's movie casting choices, using it as a reason to argue against his appointment to Disney's board.
$Masimo(MASI.US$ 's stock surged by 13% on news from the Wall Street Journal that Politan Capital Management is looking to propose two additional m...
34
1
BioNTech's revenue forecasts have been downgraded, with earnings outlook slashed from profit to loss. The company's revenues are expected to underperform the wider industry, leading to increased pessimism about the business's intrinsic value.
1
Read more